InvestorsObserver
×
News Home

Freeline Therapeutics Holdings PLC (FRLN) Stock: Do Analysts Think You Should Accumulate?

Monday, November 22, 2021 10:02 AM | InvestorsObserver Analysts

Mentioned in this article

Freeline Therapeutics Holdings PLC (FRLN) Stock: Do Analysts Think You Should Accumulate?

Analysts who follow Freeline Therapeutics Holdings PLC (FRLN) on average expect it to climb 566.67% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns the stock an Analyst Ranking of 59, which means it ranks higher than 59 of stocks, based on data compiled by InvestorsObserver.

Overall Score - 4.6
Wall Street analysts are rating FRLN a Strong Buy today. Find out what this means to you and get the rest of the rankings on FRLN!

Why are Analyst Ratings Important?

Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers. InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.

What's Happening With Freeline Therapeutics Holdings PLC Stock Today?

Freeline Therapeutics Holdings PLC (FRLN) stock is trading at $2.40 as of 9:57 AM on Monday, Nov 22, a decline of -$0.06, or -2.45% from the previous closing price of $2.46. The stock has traded between $2.38 and $2.47 so far today. Volume today is 81,198 compared to average volume of 96,509. Click Here to get the full Stock Report for Freeline Therapeutics Holdings PLC stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App